Streetbeat News

SGTX

Sigilon Therapeutics Inc

Employees

Industry

Pharmaceutical Preparation Manufacturing

harnessing the full power of cell therapeutics. cambridge, ma

Open

22.90

Mkt cap

56M

Volume

82K

High

23.08

P/E Ratio

-1.52

52-wk high

28.00

Low

22.09

Div yield

N/A

52-wk low

3.77

Eli Lilly (NYSE:LLY) has announced the acquisition of Sigilon Therapeutics (NASDAQ:SGTX) for $309.60 million in cash, expected to be completed in Q3 of 2023. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Sigilon Therapeutics is a clinical-stage biopharmaceutical company developing a new class of therapeutics for patients with chronic diseases.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 3:10 pm

US stocks traded higher with the Dow Jones gaining over 100 points. The US economy expanded by an annualized rate of 2% in Q1, higher than the 1.3% growth in the second estimate. Sigilon Therapeutics (SGTX) shares shot up 547% after Eli Lilly agreed to acquire the company. Shares of Eco Wave Power Global (WAVE) and Immunome (IMNM) also rose significantly. However, shares of BioXcel Therapeutics (BTAI), Greenlane Holdings (GNLN), and Mobiquity Technologies (MOBQ) fell.

Portfolio Pulse from Lisa Levin

June 29, 2023 | 2:10 pm

Eli Lilly And Co (NYSE:LLY) has agreed to acquire Sigilon Therapeutics Inc (NASDAQ:SGTX) for a purchase price of $14.92 per share in cash, totaling approximately $34.6 million. Sigilon is also entitled to one non-tradeable contingent value right per share to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash. The transaction is expected to close in the third quarter of 2023. Sigilon's shares are up 488.80% at $23.14.

Portfolio Pulse from Vandana Singh

June 29, 2023 | 1:41 pm

During Thursday's pre-market session, several healthcare stocks saw significant movement. Sigilon Therapeutics (NASDAQ:SGTX) stock increased by 657.8% to $29.78, while RenovoRx (NASDAQ:RNXT), Kintara Therapeutics (NASDAQ:KTRA), Immunome (NASDAQ:IMNM), Plus Therapeutics (NASDAQ:PSTV), and DermTech (NASDAQ:DMTK) also saw increases. On the other hand, BioXcel Therapeutics (NASDAQ:BTAI), Cormedix (NASDAQ:CRMD), Surgalign Holdings (NASDAQ:SRGA), Black Diamond Therapeutic (NASDAQ:BDTX), Minerva Neurosciences (NASDAQ:NERV), and Dermata Therapeutics (NASDAQ:DRMA) saw declines.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 1:12 pm

Eli Lilly has agreed to acquire Sigilon Therapeutics for $14.92 per share in cash. This has led to a surge in Sigilon's share price.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:22 pm

Eli Lilly has agreed to acquire Sigilon Therapeutics. The deal involves a tender offer to acquire all outstanding shares of Sigilon for $14.92 per share in cash, plus one non-tradeable contingent value right per share that could add up to an additional $111.64 per share in cash. The total potential consideration could reach up to $126.56 per share in cash, amounting to approximately $309.6 million excluding shares held by Lilly.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 10:50 am

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and lowers the price target from $91 to $7.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:53 am

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $2 to $91.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:00 pm

Sigilon Therapeutics (NASDAQ:SGTX) reported Q1 sales of $4.86 million and a loss of $7.38 million, with a Return On Capital Employed (ROCE) of -0.22%. The negative ROCE suggests that management may not be effectively allocating their capital.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 2:53 pm

ZIM Integrated Shipping Services shares dropped 13.9% after reporting a YoY decrease in Q1 EPS results and worse-than-expected sales results. Other stocks experienced significant gains and losses during Monday's mid-day session.

Portfolio Pulse from Lisa Levin

May 22, 2023 | 5:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.